M&A and equity raisings

6,065 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds

US deals dated after 30 September 2026 are still being collected.

Deal size
Custom range

76 deals · US$92bndisclosed · Pharma · Clear

Columns
M&A deals and equity raisings
Date Target Vendor Acquirer Type Status Value US$m Sector Advisers
Mar 2026 Novartis India Novartis AGWaveRise InvestmentsAcquisitionAnnounced–Pharma Freshfields (sell-side)
Mar 2026 Corstasis Therapeutics –Esperion TherapeuticsAcquisitionCompleted75.0Pharma+1 PJT Partners (sell-side)Arnold & Porter (sell-side)Jefferies (buy-side)Gibson Dunn (buy-side)
Mar 2026 Transcend Therapeutics –OtsukaAcquisitionAnnounced700.0Biotech+2 Kirkland & Ellis (sell-side)Goodwin (sell-side)Centerview Partners (sell-side)Skadden, Arps, Slate, Meagher & Flom (buy-side)
Mar 2026 Paratek Pharmaceuticals ––MergerCompleted–Pharma Skadden, Arps, Slate, Meagher & Flom
Mar 2026 Manufacturing facility in Phoenix, AZ Bristol Myers SquibbRoviAsset saleCompleted–Pharmaceutical Manufacturing+1 William Blair
Feb 2026 AiCuris Anti-infective Cures AG –Veloxis PharmaceuticalsAcquisitionAnnounced913.0Pharma+1 Gibson Dunn (sell-side)Freshfields (buy-side)
Feb 2026 Avadel Pharmaceuticals –AlkermesSchemeCompleted–Pharma+1 Goldman Sachs (sell-side)Morgan Stanley (sell-side)J.P. Morgan (buy-side)
Feb 2026 Orna Therapeutics –Eli Lilly and CompanyAcquisitionAnnounced2,400.0Biotech+1 Lazard (sell-side)Goodwin (sell-side)Paul, Weiss (buy-side)
Feb 2026 Apex Healthcare Berhad –Quadria Capital-led consortiumAcquisitionAnnounced–Pharma+1 Latham & Watkins (buy-side)
Jan 2026 TerSera Infusion Specialty Therapies Business Unit (IST) TerSera TherapeuticsESTEVEAsset salePending–Pharma Kirkland & Ellis (sell-side)Leerink Partners (sell-side)Perella Weinberg Partners (buy-side)Arnold & Porter (buy-side)
Jan 2026 Radius Health Patient Square CapitalB-FLEXION Life SciencesAcquisitionAnnounced–Pharma Kirkland & Ellis (sell-side)Centerview Partners (sell-side)
Jan 2026 Ventyx Biosciences –Eli Lilly and CompanyAcquisitionAnnounced1,200.0Biotech+2 Jefferies (sell-side)Moelis & Company (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)BofA Securities (buy-side)Ropes & Gray (buy-side)
Jan 2026 Nivagen Pharmaceuticals –PAI PharmaAcquisitionAnnounced–Pharmaceutical Manufacturing+1 Bourne Partners (buy-side)Kirkland & Ellis (buy-side)KPMG (buy-side)
Jan 2026 PTC Therapeutics' remaining royalty on Roche's Evrysdi PTC TherapeuticsRoyalty PharmaAsset saleAnnounced240.0Specialty finance and leasing+2 Goodwin (buy-side)
Jan 2026 Biogaran ServierBC PartnersAcquisitionAnnounced–Pharma Lazard
Jan 2026 Wonderbelly –Procter & GambleAcquisitionCompleted–Consumer Health+1 Perella Weinberg Partners (sell-side)
Jan 2026 Lantheus SPECT business LantheusSHINE TechnologiesAsset saleAnnounced–Pharma+2 Solomon Partners (sell-side)
2026 Istituto Biochimico Italiano Giovanni Lorenzini (IBI Lorenzini) –ACS DobfarAcquisitionAnnounced–Pharmaceutical Manufacturing+1 Lincoln International (sell-side)
2026 Egetis –ANI PharmaceuticalsAcquisitionAnnounced560.0Pharma+1 Centerview Partners (sell-side)
Dec 2025 Dynavax Technologies –SanofiAcquisitionAnnounced2,200.0Biotech+1 Centerview Partners (sell-side)Goldman Sachs (sell-side)Cooley (sell-side)Weil, Gotshal & Manges (buy-side)
Dec 2025 Amicus Therapeutics –BioMarinAcquisitionAnnounced4,800.0Biotech+2 Centerview Partners (sell-side)Goldman Sachs (sell-side)Kirkland & Ellis (sell-side)Morgan Stanley (buy-side)Jones Day (buy-side)
Dec 2025 MindWave Innovations –Apimeds Pharmaceuticals USMergerCompleted–Biotech+1 Duane Morris (sell-side)Nelson Mullins Riley & Scarborough (buy-side)
Sep 2025 Zentiva Advent InternationalGTCRAcquisitionAnnounced–Pharma+1 Goldman Sachs (sell-side)PJT Partners (sell-side)Freshfields (sell-side)Barclays (buy-side)BNP Paribas (buy-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side)
Jul 2025 Altanine –Polomar Health ServicesMergerPending–Healthcare+1
Jun 2025 Felix Pharmaceuticals Pvt –Advent InternationalStakeAnnounced–Animal Health+2 A&L Goodbody LLPLincoln International (sell-side)Guggenheim Securities (buy-side)
– Telomir Pharmaceuticals ––MergerAnnounced47.1Biotech+1

Deals come from stock exchange announcements and filings, takeover and scheme documents, prospectuses, the advisers' own deal announcements and the press. How the data is built All countries counts every deal, wherever it is, including deals whose geography is not known.Country pages cover Australia, New Zealand and the United States. The United Kingdom, Canada, Singapore, China and India are planned.